EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. It selectively blocks those three key pathogenic cytokines while preserving non-pathogenic signaling related to IL-4, IL-7 and IL-21 and has demonstrated clinical proof-of-concept as a novel cytokine inhibitor through a completed Phase 1/2 study in cutaneous T cell lymphoma (CTCL), a dermato-oncology indication.

EQ302 is a first-in-class, second generation, orally delivered stapled peptide inhibitor of IL-15 and IL-21 derived from EQ102, a subcutaneously administered molecule. It was developed by leveraging our in-silico, protein structure and molecular design expertise, and then employing clinically validated technologies to confer increased stability and permeability in the gastrointestinal (GI) tract. IL-15 and IL-21 are two cytokines central to T and B cell activity that exhibit biological synergy driving aggressive inflammatory responses in a number of gastrointestinal and skin diseases, highlighting the importance of dual inhibition.

Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells, reported positive data from the Phase 1b EQUATE study in patients with acute graft-versus-host disease (aGVHD) and is now being evaluated in the Phase 3 EQUATOR study. It also recently completed a Phase 1b clinical study of patients with lupus/lupus nephritis.